EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

<u>Research Article</u> ISSN 2394-3211 EJPMR

# SYNTHESIS, CHARACTERIZATION AND CYTOTOXIC STUDIES OF NEW THIAZOLIDINONES

## Shafia Mir<sup>1</sup>, Masrat Jan<sup>1</sup>, Praveen Kumar<sup>#,1</sup> and Ayaz Mahmood Dar<sup>\*,2</sup>

<sup>1</sup>Department of Chemistry, OPJS University, Churu 331001, Rajasthan, India. <sup>2</sup>Department of Chemistry GDC Kulgam (University of Kashmir), 192231, J&K, India.

#### \*Corresponding Author: Prof. Praveen Kumar

Department of Chemistry, OPJS University, Churu 331001, Rajasthan, India.

Article Received on 17/08/2018

Article Revised on 07/09/2018

Article Accepted on 27/09/2018

#### ABSTRACT

A new series of substituted aromatic thiazolidinones (5-8) were synthesized by the reaction of acetophenone and its derivatives (1-4) with hydrazine hydrate and merceptoacetic acid in absolute ethanol in one pot manner. The striking feature of this reaction is the formation of hydrazone *in situ* which in turn undergoes the cyclization with mercepto acetic acid, leading to the formation of new thiazolidinones. Thus the thiazolidinone ring closes at carbonyl carbon, by the attack of sulfur of mercaptoacetic acid moiety, preferentially from the front ( $\beta$ , axial) so that the nitrogen has an equatorial orientation ( $\alpha$ , equatorial) to avoid steric repulsion, giving minimum steric hindrance. The new compounds were characterized by spectral (IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR, MS) and analytical methods. The new compounds were screened for cytotoxicity (MTT assay) as well as genotoxicity (Comet assay) studies against different cancer cell lines, during which the new compounds depicted potential anticancer behaviour.

**KEYWORDS:** A new series of substituted aromatic thiazolidinones potential anticancer behaviour.

#### INTRODUCTION

Heterocycles have been accredited with a great amount of attention over the years by medicinal chemists for drug discovery. The interesting structural and stereochemical features of the heterocyclic compounds provide additional fascination to the researchers and thereby alterations in the skeleton have been envisaged to discover new chemical entities with a potential to afford some promising drugs of the future. The incorporation of a heterocyclic ring like thiazolidinone, thiazole or a heteroatom in the heterocyclic backbone affects the chemical properties of a heterocycle and often results in useful alterations in its biological activities.<sup>[1]</sup> Therefore, researchers are on a continuous pursuit to design and produce better heterocyclic derivatives, by following natural models. The discovery of several biologically active heterocyclic derivatives with their wide applications in therapy has also brought about an interesting interest.<sup>[1]</sup>

Thiazolidinones which is an important class of heterocyclic compounds are classified as doubly unsaturated five membered heterocyclic compounds contain one nitrogen, one sulphur and three carbon atoms including a carbonyl group. Thiazolidinones have been reported to show versatile pharmacological activities. They have been reported as COX-1 inhibitor<sup>[2]</sup>, anti-inflammatory<sup>[3]</sup>, antiproliferative,<sup>[4,5]</sup> antihistaminic<sup>[6]</sup>, anti-HIV<sup>[7,8]</sup>, hypnotic<sup>[9]</sup>, anaesthetic<sup>[10]</sup>, antifungal<sup>[11]</sup>,

anthelmintic<sup>[12]</sup> and antiviral<sup>[13]</sup> agents as well as CNS<sup>[14]</sup> stimulants. 4-thiazolidinones and their derivatives<sup>[15]</sup> exhibit unusually high activity against *Mycobacterium tuberculosis*. Recently, a number of 4-thiazolidinones derivatives found to exhibit highly potent and selective anti-Platelet activating factor activity both *in vitro* and *in vivo*.<sup>[16]</sup> 2-Arylimino-4-thiazolidinone derivatives have also showed antibacterial,<sup>[17,18]</sup> antifungal,<sup>[19]</sup> and anticonvulsant activities.<sup>[20,21]</sup> Keeping in view the applications of heterocycles and in continuation of previous work<sup>[22]</sup> we herein report the synthesis and anticancer studies of aromatic appended thiazolidinone derivatives.

## Experimental

## Chemistry

All the melting points were determined in degrees Celsius on a Kofler apparatus and are uncorrected. The IR spectra were recorded on KBr pellets with Perkin Elmer RXI Spectrophotometer and values are given in cm<sup>-1</sup>. <sup>1</sup>H and <sup>13</sup>C NMR spectra were run in CDCl<sub>3</sub> on a JEOL Eclipse (400 MHz) instrument with TMS as internal standard and values are given in ppm ( $\delta$ ). Mass spectra were recorded on a JEOL SX 102/DA-6000 Mass Spectrometer. Thin layer chromatography (TLC) plates were coated with silica gel G and exposed to iodine vapors to check the homogeneity as well as the progress of reaction. Petroleum ether refers to a fraction of boiling point 60-80°C. Sodium sulfate (anhydrous) was used as a drying agent. All the chemicals were purchased from Merck India and were used after distillation.

#### General method of synthesis of 3-amino-2-methyl-2phenyl thiazolidinone (5-8)

Acetophenone and its derivatives (5-8) (1 mmol), hydrazine hydrate (1 mmol), mercaptoacetic acid (3.0 mmol) and few drops of conc. HCl were reflux in ethanol for 5 h. The progress and completion of the reaction was monitored by TLC. After completion of reaction, the excess solvent was reduced to three fourths of the original volume under reduced pressure. The reaction mixture was then taken in ether, washed with water and dried over anhydrous sodium sulfate. Evaporation of solvents and crystallization from methanol afforded the corresponding thiazolidinones (5-8).

#### 3-Amino-2-methyl-2-phenyl thiazolidin-4-one (5)

Yield (68%); Mp: 149 °C; Anal. Calcd for  $C_{10}H_{12}N_2OS$ : C, 57.67; H, 5.81; N, 13.45; found; C, 57.57, H, 5.71, N, 13.34; IR (KBr)  $\nu$  cm<sup>-1</sup> 3215 (NH<sub>2</sub>), 1645 (C=O), 1229 (C-N), 647 (C-S); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$  7.35 (s, 1H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O),  $\delta$  4.2 (s, 3H, CH<sub>3</sub>), 3.36 (s, 2H, CH<sub>2</sub>), 6.4-6.9 (m, 5H, aromatic); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz)  $\delta$  173 (C=O), 121-130 (6C, aromatic), 48 (C-N), 38 (CH<sub>2</sub>). MS (EI): (*m*/*z*) 208 [M<sup>+-</sup>].

#### 3-Amino-2-methyl-2-(3'-hydroxyl)phenyl thiazolidin-4-one (6)

Yield (71%); Mp: 154 °C; Anal. Calcd for  $C_{10}H_{12}N_2O_2S$ : C, 57.67; H, 5.81; N, 13.45; found; C, 57.57, H, 5.71, N, 13.34; IR (KBr)  $v \text{ cm}^{-1}$  3358 (OH), 3218 (NH<sub>2</sub>), 1678 (C=O), 1234 (C-N), 1080 (C-O), 680 (C-S); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$  8.2 (s, 1H, OH, exchangeable with D<sub>2</sub>O),  $\delta$  7.5 (s, 1H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O),  $\delta$  4.2 (s, 3H, CH<sub>3</sub>), 3.38 (s, 2H, CH<sub>2</sub>), 6.4-6.6 (m, 4H, aromatic); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz)  $\delta$  176 (C=O), 121-134 (6C, aromatic), 49 (C-N), 40 (CH<sub>2</sub>); MS (EI): (m/z) 224 [M<sup>+</sup>].

#### 3-Amino-2-methyl-2-(4'-hydroxyl)phenyl thiazolidin-4-one (7)

Yield (71%); Mp: 155 °C; Anal. Calcd for  $C_{10}H_{12}N_2O_2S$ : C, 57.67; H, 5.81; N, 13.45; found; C, 57.57, H, 5.71, N, 13.34; IR (KBr)  $\nu$  cm<sup>-1</sup> 3336 (OH), 3220 (NH<sub>2</sub>), 1671 (C=O), 1229 (C-N), 1080 (C-O), 667 (C-S); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$  8.0 (s, 1H, OH, exchangeable with D<sub>2</sub>O),  $\delta$  7.3 (s, 1H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O),  $\delta$  4.2 (s, 3H, CH<sub>3</sub>), 3.35 (s, 2H, CH<sub>2</sub>), 6.1-6.3 (m, 4H, aromatic); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz)  $\delta$  172 (C=O), 121-129 (6C, aromatic), 47 (C-N), 44 (CH<sub>2</sub>); MS (EI): (m/z) 224 [M<sup>+</sup>].

# 3-Amino-2-methyl-2-(2', 4'-dihydroxyl)phenyl thiazolidinone (8)

Yield (71%); Mp: 160°C; Anal. Calcd for  $C_{10}H_{12}N_2O_3S$ : C, 49.99; H, 5.03; N, 11.66; found; C, 49.80, H, 5.00, N, 11.47; IR (KBr)  $\nu$  cm<sup>-1</sup> 3321, 3318 (OH), 3236 (NH<sub>2</sub>), 1679 (C=O), 1229 (C-N), 1080 (C-O), 667 (C-S); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$  8.2, 8.0 (s, 1H, 2×OH, exchangeable with D<sub>2</sub>O),  $\delta$  7.5 (s, 1H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O),  $\delta$  4.2 (s, 3H, CH<sub>3</sub>), 3.44 (s, 2H, CH<sub>2</sub>), 6.2-6.4 (m, 3H, aromatic); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz)  $\delta$  174 (*C*=O), 121-131 (6C, aromatic), 50 (C-N), 43 (CH<sub>2</sub>); MS (EI): (*m*/*z*) 240 [M<sup>+-</sup>].

#### Anticancer activity

Cell lines and culture conditions: Human cancer cell lines used for the study were A545 (lung carcinoma (CRL-2579), MCF7 (breast cancer cells)/ATCC cells)/ATCC (HTB-22), HeLa (cervical cancer cells)/ATCC (CCL-2), HL-60 (Leukaemia cells)/ATCC (CCL-240), SW480 (colon adenocarcinoma cells)/ATCC (CCL-228), HepG2 (hepatic carcinoma cells)/ATCC (CRL-8065), HT-29 (colon cancer cells)/ATCC (HTB-38), DU145 (pancreatic cancer cells)/ ATCC (HTB-81) and A549 (lung carcinoma cells)/ATCC (CCL-185) were obtained from National Cancer Institute (NCI), biological testing branch, Federick Research and Development Centre, USA. SW480, A549, A545, HL-60, HT29, DU145 and HepG2 cells were grown in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 10U penicillin and 100µg/mL streptomycin at 37°C with 5% CO<sub>2</sub> in a humidified atmosphere. HeLa and MCF7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplanted with FCS and antibiotics as described above for RPMI 1640. Cells were passaged at preconfluent densities, using a solution containing 0.05% trypsin and 0.5 mM EDTA.

Cell viability assay (MTT): The in vitro cytotoxicity was measured using the MTT assay. The assay was carried out according to known protocol.<sup>[23]</sup> Exponentially growing cells were harvested and plated in 96-well plates at a concentration of  $1 \times 10^4$  cells/well. After 24 h incubation at 37°C under a humidified 5% CO<sub>2</sub> to allow cell attachment, the cells in the wells were respectively treated with target compounds at various concentrations for 48 h. The concentration of DMSO was always kept below 1.25%, which was found to be non-toxic to the cells. A solution of 3-(4, 5-dimethylthiazo1-2-y1)-2, 5diphenyltetrazolium bromide (MTT), was prepared at 5 mg/mL in phosphate buffered saline (PBS; 1.5 mM KH<sub>2</sub>PO<sub>4</sub>, 6.5 mM Na<sub>2</sub>HPO<sub>4</sub>, 137 mM NaCl, 2.7 mM KCl; pH 7.4) and 20 µL of this solution was added to each well. After incubation for 4 h at 37°C in a humidified incubator with 5% CO2, the medium/MTT mixtures were removed and the formazan crystals formed by the mitochondrial dehydrogenase activity of vital cells were dissolved in 100 µL of DMSO per well. The absorbance of the wells was read with a microplate reader (Bio-Rad Instruments) at 570 nm. Effects of the drug cell viability were calculated using cell treated with DMSO as control.

*Data analysis:* Cell survival was calculated using the formula: Survival (%) = [(absorbance of treated cells – absorbance of culture medium)/(absorbance of untreated cells – absorbance of culture medium)]  $\times$  100.<sup>24</sup> The experiments were done in triplicate and the inhibitory

concentration (IC) values were calculated from a dose response curve.  $IC_{50}$  is the concentration in ' $\mu$ M' required for 50% inhibition of cell growth as compared to that of control.  $IC_{50}$  values were determined from the linear portion of the curve by calculating the concentration of agent that reduced absorbance in treated cells, compared to control cells by 50%. Evaluation is based on mean values from three independent experiments, each comprising at least six micro-cultures per concentration level.

#### Comet assay (Single cell gel electrophoresis)


To assess the genotoxic effect of the new steroidal derivatives, comet  $assay^{[25]}$  was performed in MCF7 cells. The MCF7  $(1 \times 10^6)$  cells were treated with 10, 25 and 50 µg/mL of steroidal derivatives for 24 h. The cells were then washed and 200 µL of cell suspension in low melting agarose (LMA) was layered on to the labelled slides precoated with agarose (1.5%). The slides were placed on ice for 10 min. and submerged in lysis buffer (2.5% NaCl, 100 mM EDTA, 10 mM Tris, 10% DMSO and 1% Troton X-100) at 4°C at pH 10 for more than 1 h. The slides were then equilibrated in alkaline buffer (30

mM NaOH, 1 mM EDTA) at 4°C at pH 13, electrophoresed at 0.86 V/cm at 4°C, neutralized, washed and dried. At the time of capturing the images, the slides were stained with ethidium bromide (EtBr, 150  $\mu$ L 1X) and cover slips were placed over them. For visualization of DNA-damage, EtBr-stained slides were observed under 209 objectives of a fluorescent microscope (Olympus BX-51, Japan). The images of 50-100 randomly selected cells were captured per slide using a CCD camera.

#### **RESULT AND DISCUSSION**


### Chemistry

Development of highly functional molecules from simple building blocks has always been the curiosity of synthetic chemists. So we here in report the convenient route for the synthesis of new thiazolidinones (**5-8**) by reacting acetophenone and its derivatives (**1-4**) with hydrazine and merceptoacetic acid in absolute ethanol for the period of about 5 h under reflux conditions (**Scheme 1**) and on the completion of reaction, products were obtained in better yields (68-71%).



Scheme 1. Schematic representation for the formation of thiazolidinones (5-8).

The tentative mechanism for the formation of thiazolidinones (**5-8**) has been proposed in **scheme 1I**. The mechanism depicts clearly the formation of hydrazone *in situ* first by simple condensation which later undergo cyclization with merceptoacetic acid hence leads to the formation of the products (**5-8**). The structures of these compounds were characterized by spectral (IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR, MS) and analytical methods.



Scheme 1I: Proposed mechanism of formation 3-amino-2-methyl-2-phenyl thiazolidin-4-one derivatives (5-8).

#### Stereochemistry

The stereoselectivity of these thiazolidinones can be explained by considering that there is a considerable amount of steric hindrance to ring-closure from one side of the ring at Carbonyl carbon which might be explained on the basis that the sulfur atom is more bulky than nitrogen during cyclization. Thus the thiazolidinone ring closes at carbonyl carbon, by the attack of sulfur of mercaptoacetic acid moiety, preferentially from the front  $(\beta, axial)$  so that the nitrogen has an equatorial orientation ( $\alpha$ , equatorial) to avoid steric repulsion, giving minimum steric hindrance and maximum stability. This is further supported by the fact that during cyclization the nitrogen already attached to carbonyl carbon is moved towards the back ( $\alpha$ , equatorial) side to reduce the steric hindrance, and leaving the front  $(\beta,$ axial) side for the attack of nucleophile to close the thiazolidinone ring. Therefore the only product of this reaction with R stereochemistry was selectively obtained. The dreiding models also suggest the attack of sulfur from the  $\beta$ -side which pushes the nitrogen to the less hindered  $\alpha$ -side. Hence the formulation of the compound as **R** is preferred over its isomer S.

The characterization studies showed good agreement with proposed structures of thiazolidinones<sup>[26]</sup> (5-8) (Scheme 1). In their IR spectra the presence of absorption bands in the range 3215-3236 cm<sup>-1</sup> shows the presence of NH<sub>2</sub> while as the absorption bands at 1645-1679, 1620-1625 and 3318-3358 cm<sup>-1</sup> confirm the presence of C=O & CH=CH (arom.) and OH groups, respectively in the compounds (5-8). The presence of bands at 1229-1234 and 647-680 cm<sup>-1</sup> were ascribed to C-N and C-S groups, respectively. In <sup>1</sup>H NMR study of the compounds (5-8), the three downfield singlets at  $\delta$ 8.2-8.0, 7.3-7.5, 4.2 were ascribed to OH, NH<sub>2</sub> and CH<sub>3</sub> while as the presence of broad multiplet at  $\delta$  6.1-6.9 revealed the presence of aromatic protons. The presence of two proton singlet at  $\delta$  3.36-3.44 was ascribed to two methylene protons In <sup>13</sup>C NMR study, the signals at  $\delta$ 

172-176, 121-131, 47-50 and 38-44 confirm the presence of C=O, C=C (arom.), C-N and CH<sub>2</sub> groups respectively in the products (**5-8**). Finally the presence of distinct molecular ion peak [ $M^{+}$ ] at m/z: 208, 224, 224 and 240 in the MS after following the nitrogen rule, also proved the formation of compounds (**5-8**). The strategy can also be applied to diverse ketones, in that way thiazolidinones may also allow further modifications on the substituted heterocyclic systems.

#### Anticancer activity

The cytotoxicity of thiazolidinones **5-8** (**341-344**) was studied by MTT assay.<sup>[23]</sup> The data reported in **Table II** suggest that compound **5-8** (**341-344**) showed different levels of cytotoxicity. During the screening, the potential behavior was depicted by the compounds against given cancer cells. The compound **6** showed IC<sub>50</sub> = 9.63 µmol L<sup>-1</sup> (HT-29), 9.73 µmol L<sup>-1</sup> (MCF7), 11.45 µmol L<sup>-1</sup> (A549). Compound **7** also depicted minimum IC<sub>50</sub> value in the range of 12.79 µmol L<sup>-1</sup> (HT-29) and 10.60 µmol L<sup>-1</sup> (MCF7) while compound **5** showed minimum IC<sub>50</sub>=9.11 µmol L<sup>-1</sup> (A545) and 15.26 µmol L<sup>-1</sup> (HepG2) cell line.

From the **Table II** it is clear that the  $IC_{50}$  for compound **6** against A549 and HeLa cells was found to be 11.45 and 11.72  $\mu$ M L<sup>-1</sup> which is close to the  $IC_{50}$  of Cisplatin 12.0 and 9.43  $\mu$ M L<sup>-1</sup>, respectively against the same cells.  $IC_{50}$  for compound **6** against HeLa cell line was found to be 11.72  $\mu$ M L<sup>-1</sup>which were also close to the  $IC_{50}$  of Cisplatin 9.43 against the same cell line. Similarly  $IC_{50}$  for compounds **5** and **6** against HepG2 was found to be 11.26 and 13.56  $\mu$ M L<sup>-1</sup> which is also near to  $IC_{50}$  of Cisplatin 9.8 against same cell line.

IC <sub>50</sub> (μM L <sup>-1</sup> )											
Comp.	Lung				ia Colon	Hepatic	Colon	Lung			
5	<b>A545</b> 9.11	MCF7 27.39	<b>HeLa</b> 15.13	<b>HL-60</b> >50	<b>SW480</b> 26.11	HepG2 15.26	<b>HT-29</b> 17.12	<b>A549</b> 16.31			
6	13.45	9.73	11.72	20.17	12.81	11.01	9.63	11.45			
7	16.53	10.60	17.37	28.34	>50	24.37	12.79	20.64			
8	17.24	21.33	14.22	>50	>50	13.56	14.87	22.31			
Cisplatin	8.9	9.3	9.43	7.83	3.52	9.80	7.24	12.0			
5-FU	15.4	15.3	16.32	>50	15.71	>50	9.79	12.8			

Table II.	The IC <sub>50</sub> o	f compounds	(5-8)	) against	cancer	cells.
I apic II.	11010500	i compoundo	0-0	agamoi	cancer	cons.


5-FU = 5-Fluorouracil


It can be concluded that compound **6** and **7** showed potential *in vitro* cytotoxicity against A549, HeLa, HepG2 and A545 cell lines by depicting  $IC_{50}$  close to that of Cisplatin, thus can be considered as potential cytotoxic agents. Compound **5-8** also showed marked cytotoxicity against HL-60 and HepG2 cell lines by showing  $IC_{50}$  less than standard drug, 5-fluorouracil.

#### 2. Comet assay

To understand the apoptotic degradation of DNA, the compound **5-8** were screened against MCF7 in comet assay. There was dose-dependent increase in the tail length when cells were treated with compound **5-8**.


Compound **6** presented maximum apoptotic DNA damage among the three thiazolidinone studied, which is in accordance with its maximum cytotoxicity as seen in MTT assay. The quantified increase in DNA damage suggested that the thiazolidinone derivative **6** induced dose-dependent fragmentation of chromosomal DNA leading to apoptosis. The images of comet assay for control, cells treated with compound **5-8** ( $50\mu$ g/mL) are depicted in **Fig. I**. Slides were analysed for parameter like tail length (TL), using image analyzer CASP software version 1.2.2. The results of the assay for tail length are shown in **Fig. II**.






**Control (Untreated)** 

Fig. I: Detection of DNA damage in MCF7 cells. Treated cells (24 h) were layered over agarose gel, lysed, electrophoresed in alkaline buffer and stained with propidium iodide.





#### CONCLUSION

The operationally simple reaction for convenient synthesis of thiazolidinones was successfully developed. The reaction got completed in almost 5 h and on completion; potential yields were obtained. This strategy offered a very straight forward, one-pot and efficient method for access to new thiazolidinones. The compounds successfully revealed the cytotoxic and genotoxic behaviour against the different cancer cell lines. In conclusion, the present study showed that these one pot synthesized compounds can be used as a template for future development through modification and derivatization to design more potent and selective anticancer agents.

## ACKNOWLEDGEMENTS

The authors thank Head of Chemistry Department OPJS University for successful completion of the work.

## REFERENCES

- Singh, H. Kapoor, V.K. Paul, D. (1979). *Heterosteroids and drug research. In: Progress in Medicinal Chemistry*, Ellis GP, West GB. Eds., Springer: Amsterdam, p. 35.
- Chirag, K.P. Rami, C.S. Panigrahi, B. Patel, C.N. (2010). Synthesis and biological evaluation of (4substituted benzylidene)-3- methyl-1-(substituted phenyl sulfonyl and substituted benzoyl)-1Hpyrazol-5(4H)-one as anti-inflammatory agent. J Chem Pharm Res., 2: 73-77.
- Michon, V. Penhoat, C.H.D. Tombret, F. Gillardin, J.M. Lepagez, F. Berthon, L. (1995). Preparation, structural analysis and anticonvulsant activity of 3and 5-aminopyrazole N-benzoyl derivatives. Eur J Med Chem., 30: 147-152.
- Janus, S. L. Magdif, A. Z. Erik, B. P. Claus, N. (1999). Synthesis of triazenopyrazole derivatives as potential inhibitors of HIV-1. Monatsh fur Chem., 130: 1167-1171.
- Kees, K.L. Fitzgerald, J.J.J. Steiner, K.E. Mattes, J.F. Mihan, B. Tosi, T. Mondoro, D. McCaleb, M.L. (1996). New potent antihyperglycemic agents in db/db mice: synthesis and structure-activity relationship studies of (4-substituted benzyl) (trifluoromethyl) pyrazoles and –pyrazolones. J Med Chem., 39: 3920.
- Shamsuzzaman, Aslam, M. Salim, A. (1998). Stereoselective Synthesis of Steroidal (6R)-Spiro-1', 3', 4'-Thiadiazolines. J Chem Res., 824-827.
- Himly, M. Jahn-Schmid, B. Pittertschatscher, K. Bohle, B. Grubmayr, K. Ferreira, F. Ebner, H. Ebner, C. (2003). IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J. Allergy Clin Immunol, 111: 882-886.
- Watanabe T., Yuki, S. Egawa, M. Nishi, H. (1994). Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther., 268: 1597-1601.

- 9. Wu, T. W. Zeng, L. H. Wu, J. Fung, K. P. (2002) Myocardial protection of MCI-186 in rabbit ischemia-reperfusion. Life Sci., 71: 2249-2252.
- Al-Haiza, M.A. El-Assiery, S.A. Sayed, G.H. (2001) Synthesis & potential antimicrobial activity of new compounds containing the pyrazol-3-one moiety. Acta Pharm 51: 251-256.
- Castagnolo, D. Manetti, F. Radi, M. Bechi, B. Pagano, M. De Logu, A. Meleddu, R. Saddi, M. Botta, M. (2009). Bioorg Med Chem 17, 5716-5721
- 12. Stanovnik, B. and Svete, J. (2002). Houben-Weyl Methods of Molecular Transformations. Sci Synth, 12: 220-223.
- 13. Tong, A. Akama, Y. Tanaka, S. (1989). Reversedphase high-performance liquid chromatography of aluminium(III) and indium(III) with 1-phenyl-3methyl-4-benzoyl-5- pyrazolone J Chrom, 478: 408-412.
- Samelson, H. and Lempicki, A. (1963). Fluorescence and Lifetimes of Eu Chelates J Chem Phys., 39: 110-115.
- 15. Visvanathan, K. and Davidson, N. E. (2003). Aromatase inhibitors as adjuvant therapy in breast cancer. Oncology, 17: 335-339.
- 16. Li, X. Singh, S.M., Cote, J. Laplante, S. Veilleux, R. (1995). Synthesis and in vitro evaluation of 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene- $17\beta$ -carboxamides as  $5\alpha$ -reductase inhibitors and antiandrogens. J Med Chem, 38: 1456-1461.
- 17. Dias, R.S. and Lindman, B. (2008). DNA Interactions with Polymers and Surfactants, Wileyand Sons, New Jersey, pp. 2.
- Girod, J.C. Johson, W.C.J. Huntington, S.K. Maestre, M.F. (1983). Conformation of deoxyribonucleic acid in alcohol solutions. Biochemistry, 12: 5092-5096.
- Meng, X. Liu, L. Zhou, C. Wang, L. Liu, C. (2008). Dinuclear Copper(II) Complexes of a Polybenzimidazole Ligand: Their Structures and Inductive Roles in DNA Condensation. Inorg Chem., 47: 6572-6574.
- Wilson, R.W. Bloomfield, V.A. (1979). Counterioninduced condesation of deoxyribonucleic acid. a light-scattering study. Biochemistry, 18: 2192-2196.
- Cohen, P. Kidson, C. (1968). Conformational analysis of DNA-poly-l-lysine complexes by optical rotatory dispersion. J Mol Biol., 35: 241-245.
- 22. (a) Dar, A.M. Nabi, R. Mir, S. Gatoo, M.A. Shamsuzzaman, Lone, S.H. (2018) Synthesis of steroidal imidazolidinthiones as potential apoptotic agents: Investigation by theoretical and experimental studies. Bioorganic Chemistry, 79: 190-200. (b) Dar, A.M. Mir, S. Jan, M. Shamsuzzaman. (2017). Spectroscopic studies of newly synthesized steroidal dihydropyrroles. Eur Chem Bull, 6(7): 321-324. (c) Dar, A.M. Rah, B. Mir, S. Nabi, R. Shamsuzzaman, Gatoo, M.A. Mashrai, A. Khan, Y. (2018) DNA binding, artificial nuclease activity and cytotoxic studies of newly synthesized steroidal pyrimidines.

International Journal of Biological Macromolecules, 111: 52-61.

- Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65: 55-63.
- 24. Saxena, H.O. Faridi, U. Kumar, J.K. Luqman, S. Darokar, M.P. Shanker, K. Chanotiya, C.S. Gupta, M.M. Negi, A.S. (2007). Synthesis of chalcone derivatives on steroidal framework and their anticancer activities. Steroids, 72: 892-900.
- 25. Singh, N.P. (2000) Microgels for estimation of DNA-strand breaks, DNA protein crosslinks and apoptosis. Mutat Res., 455: 111-127.